Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid Prior to Parathyroidectomy in Primary Hyperparathyroidism
NCT06859580Phase 4Recruiting
- Sponsor
- Aarhus University
- Start
- Mar 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in primary hyperparathyroidism (PHPT) comparing Zoledronic acid with Placebo (2 arms). Primary endpoint: Areal Bone Mineral Density at lumbar spine at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
primary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on NCT06859580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859580.